Literature DB >> 6117439

Metabolism of methylphenidate in dog and rat.

H Egger, F Bartlett, R Dreyfuss, J Karliner.   

Abstract

The urinary metabolites of methylphenidate in the dog and rat were investigated. After oral administration of 14C-labeled methylphenidate, approximately 86% and 63% of the dose was recovered in the urine of the dog and rat, respectively. Less than 1% of the dose was excreted as unchanged drug. Metabolism involved oxidation, hydrolysis, and conjugation processes. The primary hydrolytic product was alpha-phenyl-2-piperidineacetic acid (24%, dog; 35-40%, rat). The primary metabolites of oxidation were methyl 6-oxo-alpha-phenyl-2-piperidineacetate (3%, dog; 1.5%, rat) and the glucuronide of alpha-(p-hydroxyphenyl)-2-piperidineacetic acid (10%, rat). The former also underwent extensive biotransformation, including: 1) hydrolysis to the lactam acid (27%, dog; 7-10%, rat) and subsequent carboxylic acid O-glucuronidation (15%, dog); or 2) hydroxylation at the 5-position (1%, dog; 2%, rat) and subsequent hydrolysis (4%, dog; 15-17%, rat); or 3) 5-O-glucuronidation (12%, dog). Additional minor metabolites from methyl-6-oxo-alpha-phenyl-2-piperidineacetate were the phenolic O-glucuronide of methyl alpha-(p-hydroxyphenyl)-6-oxo-2-piperidineacetate (1%, dog), and the 4-O-glucuronide of methyl 4-hydroxy-6-oxo-alpha-phenyl-2-piperidineacetate (1%, dog), and the taurine amide conjugate of alpha-(p-hydroxyphenyl)-6-oxo-2-piperidineacetic acid (1%, dog). Additional products from methylphenidate conjugation included methyl 1-carbamoyl-alpha-phenyl-2-piperidineacetate (1%, dog or rat) and its carboxylic acid hydrolysis product (1%, rat). The chirality of the major metabolites isolated from dog urine showed that metabolism was partially stereoselective in all investigated cases, except in the formation of alpha-phenyl-2-piperidineacetic acid.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117439

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 2.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 3.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations.

Authors:  Guinevere H Bell; Andrew J Novak; William C Griffin; Kennerly S Patrick
Journal:  J Pharm Sci       Date:  2011-01-14       Impact factor: 3.534

5.  Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase.

Authors:  Jianhua Zhang; Yulin Deng; Jim Fang; Gordon McKay
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

6.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

7.  Capillary electrophoresis-mass spectrometry-based detection of drugs and neurotransmitters in Drosophila brain.

Authors:  Nhu T N Phan; Jörg Hanrieder; E Carina Berglund; Andrew G Ewing
Journal:  Anal Chem       Date:  2013-08-19       Impact factor: 6.986

8.  Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates.

Authors:  Xiaoxia Yang; Suzanne M Morris; Jeffery M Gearhart; Christopher D Ruark; Merle G Paule; William Slikker; Donald R Mattison; Benedetto Vitiello; Nathan C Twaddle; Daniel R Doerge; John F Young; Jeffrey W Fisher
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

Review 9.  From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate.

Authors:  Francesco Paolo Busardò; Chrystalla Kyriakou; Luigi Cipolloni; Simona Zaami; Paola Frati
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.